Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer

Urology. 2004 Oct;64(4):637-42. doi: 10.1016/j.urology.2004.04.047.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Apoptosis / physiology
  • Carcinoma / drug therapy*
  • Carcinoma / enzymology
  • Carcinoma / pathology
  • Carcinoma / prevention & control*
  • Cell Movement / physiology
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacokinetics
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Cytokines / physiology
  • Drug Screening Assays, Antitumor
  • Enzyme Induction / drug effects
  • Humans
  • Immune Tolerance / physiology
  • Inflammation / drug therapy
  • Inflammation / enzymology
  • Inflammation / prevention & control
  • Membrane Proteins
  • Mice
  • Neoplasm Invasiveness
  • Neovascularization, Pathologic / enzymology
  • Neovascularization, Physiologic / physiology
  • Prostaglandin-Endoperoxide Synthases / physiology*
  • Prostaglandins / metabolism
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / enzymology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / prevention & control*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Cytokines
  • Membrane Proteins
  • Prostaglandins
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases